Skip to main content

Table 6 Causes of durvalumab discontinuation

From: Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC

  Frequency %
Still ongoing 7 29.2
Adverse events 3 12.5
Disease progression 9 37.5
All dose received (as planned) 5 20.8